Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

MoonLake Immunotherapeutics (MLTX) Preferred Stock Liabilities (2020 - 2021)

MoonLake Immunotherapeutics' Preferred Stock Liabilities history spans 2 years, with the latest figure at $115.0 million for Q4 2021.

  • Quarterly Preferred Stock Liabilities changed 0.0% to $115.0 million in Q4 2021 from the year-ago period, while the trailing twelve-month figure was $115.0 million through Dec 2021, changed 0.0% year-over-year, with the annual reading at $115.0 million for FY2021, 0.0% changed from the prior year.
  • Preferred Stock Liabilities came in at $115.0 million for Q4 2021, roughly flat from $115.0 million in the prior quarter.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $115.0 million in Q4 2020 to a low of $107.3 million in Q2 2021.